News

and James Cavuoto, editor July 2020 issue Vendors of implanted neuromodulation systems have turned increasingly to new smartphone apps to enable patients to exert more control over their therapeutic regimens. The apps also offer clinicians an increased opportunity for remote medicine at a time when the coronavirus pandemic has made office visits less tenable. Last year, Boston Scientific introduced…

About 70 neurotechnology industry professionals participated in the first annual Neurotech Commercialization Workshop, which took place on the Zoom platform earlier this month. The event was targeted at neurotech startups and existing neuromodulation device firms developing new product technologies. During the workshop Neurotech Reports editors James Cavuoto, Jennifer French, Jeremy Koff, and Jo Jo…

As is the case with all forms of DBS therapy, success with DBS for obsessive-compulsive disorder depends heavily on the accurate placement of electrodes and requires millimeter-level precision. The optimal stimulation target for OCD has not been determined definitively. But a team of researchers in Germany recently reported progress identifying the optimal target. Medtronic’s Reclaim DBS therapy received FDA approval in 2009 via the HDE pathway.

In times of economic uncertainty such as this, entrepreneurs and executives launching new products or new companies need to be certain they are maximizing their chances of success. This is one reason why our editors created the online Neurotech Commercialization Workshop [see Conference Report, p6]. In one of the afternoon breakout sessions at the first annual event, this editor led a session devoted to analyzing recent clinical trial failures in the neurotechnology industry.

In recent years, one of the most significant areas of research in biomaterials for new neural implants has been graphene. Researchers in Europe and North America have made steady progress developing devices with higher spatial resolution using the material. There is now at least one commercial startup in this space. INBRAIN Neuroelectronics, a spin-off of the Catalan Institute of Nanoscience and Na…

Mainstay Medical, the Dublin, Ireland manufacturer of neuromodulation systems, announced FDA approval of ReActiv8, its implantable restorative neurostimulation system for chronic low back pain. The FDA approval grants Mainstay the right to market ReActiv8 in the U.S. as an aid in the management of intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced in adults who have failed therapy, including pain medications and physical therapy, and are not candidates for spine surgery.

As with so many conferences held in 2020, the MDIC Annual Public Forum has transformed itself from a multi-day in-person event to a series of virtual meetings. The Medical Device Innovation Consortium is a public-private partnership that focuses on advancing medical device regulatory science for the benefit of the end-user or patient. This consortium is unique to the medical device landscape since…

Neurotech Reports announced it will offer a commercialization workshop for neurotech startups and established firms seeking to launch new products on July 8. The workshop, hosted on Zoom, will feature short courses from NBR editors James Cavuoto, Jennifer French, Jeremy Koff, and Jo Jo Platt. The free morning sessions will feature short courses devoted to preparing a pitch deck, developing a financial model, attracting early-stage investment, and assessing the market opportunity.

Neurotech Reports announced it will offer a commercialization workshop for neurotech startups and established firms seeking to launch new products on July 8. The workshop, hosted on Zoom, will feature short courses from NBR editors James Cavuoto, Jennifer French, Jeremy Koff, and Jo Jo Platt. The free morning sessions will feature short courses devoted to preparing a pitch deck, developing a financial model, attracting early-stage investment, and assessing the market opportunity.

Neurotech Reports announced it will offer a commercialization workshop for neurotech startups and established firms seeking to launch new products on July 8. The workshop, hosted on Zoom, will feature short courses from NBR editors James Cavuoto, Jennifer French, Jeremy Koff, and Jo Jo Platt. The free morning sessions will feature short courses devoted to preparing a pitch deck, developing a financial model, attracting early-stage investment, and assessing the market opportunity.